[go: up one dir, main page]

MA51230A - Protéines f rsv stabilisées et leurs utilisations - Google Patents

Protéines f rsv stabilisées et leurs utilisations

Info

Publication number
MA51230A
MA51230A MA051230A MA51230A MA51230A MA 51230 A MA51230 A MA 51230A MA 051230 A MA051230 A MA 051230A MA 51230 A MA51230 A MA 51230A MA 51230 A MA51230 A MA 51230A
Authority
MA
Morocco
Prior art keywords
stabilized
rsv proteins
rsv
proteins
Prior art date
Application number
MA051230A
Other languages
English (en)
Inventor
Andrew Bett
Eberhard Durr
Arthur Fridman
Lan Zhang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA51230A publication Critical patent/MA51230A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MA051230A 2018-01-29 2019-01-24 Protéines f rsv stabilisées et leurs utilisations MA51230A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862623184P 2018-01-29 2018-01-29

Publications (1)

Publication Number Publication Date
MA51230A true MA51230A (fr) 2021-05-05

Family

ID=67396243

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051230A MA51230A (fr) 2018-01-29 2019-01-24 Protéines f rsv stabilisées et leurs utilisations

Country Status (11)

Country Link
US (2) US11566051B2 (fr)
EP (1) EP3746462A4 (fr)
JP (1) JP7541482B2 (fr)
KR (1) KR102809623B1 (fr)
CN (1) CN111655715A (fr)
AU (1) AU2019212237B2 (fr)
BR (1) BR112020015308A8 (fr)
CA (1) CA3088546A1 (fr)
MA (1) MA51230A (fr)
MX (1) MX2020007945A (fr)
WO (1) WO2019147749A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3746090A4 (fr) 2018-01-29 2021-11-17 ModernaTX, Inc. Vaccins à base d'arn contre le vrs
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
CA3170740A1 (fr) * 2020-05-29 2021-12-02 Curevac Ag Vaccins combines a base d'acide nucleique
IL303195A (en) 2020-11-25 2023-07-01 Akagera Medicines Inc Lipid nanoparticles for delivery of nucleic acids and related methods of use
US20240115674A1 (en) * 2021-02-03 2024-04-11 The Board Of Trustees Of The University Of Illinois Vaccine and methods for preventing filariasis and dirofilariasis
CN113577258B (zh) * 2021-07-31 2024-04-16 山东兴瑞生物科技有限公司 一种双靶点mRNA疫苗及其制备方法
CN117715923A (zh) * 2022-04-29 2024-03-15 北京新合睿恩生物医疗科技有限公司 Rsv f蛋白突变体及其应用
JP2025522311A (ja) 2022-05-25 2025-07-15 アカゲラ・メディスンズ，インコーポレイテッド 核酸を送達するための脂質ナノ粒子およびその使用方法
WO2024078597A1 (fr) * 2022-10-13 2024-04-18 Rvac Medicines (Us) , Inc. Variants de la protéine f du vrs et utilisations associées
CN116478296B (zh) * 2022-10-17 2024-02-23 厦门大学 截短的呼吸道合胞病毒f蛋白及其用途
CN117050149B (zh) * 2023-05-19 2025-12-12 珠海丽凡达生物技术有限公司 包含人呼吸道合胞病毒抗原的免疫组合物及其制备方法和应用
WO2024256637A1 (fr) * 2023-06-16 2024-12-19 Glaxosmithkline Biologicals Sa Protéines vrs-f à substitution de cystéine
CN119490569A (zh) * 2023-08-16 2025-02-21 深圳瑞吉生物科技有限公司 呼吸道合胞病毒抗原性多肽、核酸、疫苗及其应用
WO2025052180A2 (fr) * 2023-09-07 2025-03-13 Axelyf ehf. Lipides et nanoparticules lipidiques
CN117567652B (zh) * 2024-01-19 2024-05-14 北京安百胜生物科技有限公司 一种重组呼吸道合胞病毒颗粒抗原
CN117586359A (zh) * 2024-01-19 2024-02-23 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽
CN118440937B (zh) * 2024-04-09 2025-02-25 嘉译生物医药(杭州)有限公司 新型的人合胞病毒RSV B mRNA疫苗
CN118496324B (zh) * 2024-05-22 2025-10-21 苏州聚微生物科技有限公司 RSV pre-F突变体及其生产方法和用途
CN118406159B (zh) * 2024-05-22 2025-07-08 苏州聚微生物科技有限公司 RSV pre-F截短体及其生产方法和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
EP1027033B1 (fr) 1997-05-14 2009-07-22 The University Of British Columbia Encapsulation hautement éfficace d'acides nucléiques dans des vésicules lipidiques
US20030077829A1 (en) 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
WO2004010935A2 (fr) * 2002-07-25 2004-02-05 Medimmune, Inc. Methodes de traitement et de prevention de rsv, hmpv, et piv a l'aide d'anticorps anti-rsv, anti-mpvh, et anti-piv
WO2004058166A2 (fr) 2002-12-23 2004-07-15 Vical Incorporated Vaccins a base de polynucleotides a codon optimise diriges contre l'infection par le cytomegalovirus humain
NZ581166A (en) 2003-09-15 2011-06-30 Protiva Biotherapeutics Inc Polyethyleneglycol-modified lipid compounds and uses thereof
AU2005248361B2 (en) 2004-05-18 2010-03-11 Vical Incorporated Influenza virus vaccine composition and methods of use
JP5042863B2 (ja) 2005-02-14 2012-10-03 サーナ・セラピューティクス・インコーポレイテッド 生物学的に活性な分子をデリバリーするための脂質ナノ粒子系組成物および方法
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
EP1997830A1 (fr) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. Molécules à liaison spécifiques RSV et leur moyen de fabrication
WO2009132131A1 (fr) 2008-04-22 2009-10-29 Alnylam Pharmaceuticals, Inc. Formulation lipidique améliorée à base d'amino lipide
EP2326331A4 (fr) 2008-08-18 2013-05-15 Merck Sharp & Dohme Nouvelles nanoparticules lipidiques et nouveaux composants pour l'administration d'acides nucléiques
WO2010042877A1 (fr) 2008-10-09 2010-04-15 Tekmira Pharmaceuticals Corporation Lipides aminés améliorés et procédés d'administration d'acides nucléiques
CA2754043A1 (fr) 2009-03-12 2010-09-16 Alnylam Pharmaceuticals, Inc. Compositions formulees de lipides et procedes d'inhibition de l'expression de genes de eg5 et de vegf
JPWO2010146740A1 (ja) 2009-06-17 2012-11-29 シャープ株式会社 表示駆動回路、表示装置及び表示駆動方法
ES2563730T3 (es) 2009-07-15 2016-03-16 Glaxosmithkline Biologicals S.A. Composiciones de proteína RSV F y procedimientos de fabricación de las mismas
US9181295B2 (en) 2009-08-20 2015-11-10 Sirna Therapeutics, Inc. Cationic lipids with various head groups for oligonucleotide delivery
SG10201407996PA (en) 2009-12-23 2015-01-29 Novartis Ag Lipids, lipid compositions, and methods of using them
JP5961170B2 (ja) 2010-09-20 2016-08-02 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． オリゴヌクレオチドの送達のための新規な低分子量カチオン性脂質
KR102032002B1 (ko) 2011-11-23 2019-10-14 머크 샤프 앤드 돔 코포레이션 알루미늄 히드록시포스페이트 아주반트의 제조 방법
WO2014160463A1 (fr) 2013-03-13 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Protéines f de rsv pré-fusion et leur utilisation
EP3556353A3 (fr) 2014-02-25 2020-03-18 Merck Sharp & Dohme Corp. Adjuvants de vaccins à nanoparticules lipidiques et systèmes d'administration d'antigènes
WO2017049245A2 (fr) 2015-09-17 2017-03-23 Modernatx, Inc. Composés et compositions pour l'administration intracellulaire d'agents thérapeutiques
MA46023A (fr) * 2015-10-22 2019-07-03 Modernatx Inc Vaccin contre le virus de la grippe à large spectre
JO3555B1 (ar) * 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
KR102136678B1 (ko) 2015-12-23 2020-07-22 화이자 인코포레이티드 Rsv f 단백질 돌연변이체
EP3436064A1 (fr) 2016-03-29 2019-02-06 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Protéines f du vrs modifiées par substitutions et sous conformation de pré-fusion, et leur utilisation

Also Published As

Publication number Publication date
RU2020128445A (ru) 2022-02-28
US20210300971A1 (en) 2021-09-30
US11566051B2 (en) 2023-01-31
EP3746462A2 (fr) 2020-12-09
JP2021511356A (ja) 2021-05-06
JP7541482B2 (ja) 2024-08-28
AU2019212237B2 (en) 2024-12-12
US12234265B2 (en) 2025-02-25
KR20200115567A (ko) 2020-10-07
WO2019147749A3 (fr) 2019-09-19
WO2019147749A2 (fr) 2019-08-01
AU2019212237A1 (en) 2020-07-30
MX2020007945A (es) 2020-09-24
BR112020015308A2 (pt) 2020-12-08
CA3088546A1 (fr) 2019-08-01
EP3746462A4 (fr) 2022-01-05
CN111655715A (zh) 2020-09-11
RU2020128445A3 (fr) 2022-02-28
BR112020015308A8 (pt) 2023-02-07
US20230141153A1 (en) 2023-05-11
KR102809623B1 (ko) 2025-05-16

Similar Documents

Publication Publication Date Title
MA51230A (fr) Protéines f rsv stabilisées et leurs utilisations
EP3817822A4 (fr) Agents de dégradation de protéines et leurs utilisations
EP3810182A4 (fr) Néoantigènes et leurs utilisations
EP3891183A4 (fr) Anticorps anti-claudine et leurs utilisations
EP3794037A4 (fr) Anticorps anti-claudine 18.2 et leurs utilisations
EP3625263A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
EP3817769A4 (fr) Anticorps anti-cd47 humains et leurs utilisations
EP3849608A4 (fr) Nouveaux anticorps anti-lilrb4 et leurs utilisations
EP3661965A4 (fr) Anticorps anti-cd47 et leurs utilisations
EP3383916A4 (fr) Anticorps anti-cd73 et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
MA49687A (fr) Anticorps anti-ctla-4 et leurs utilisations
EP3389702A4 (fr) Anticorps anti-lag-3 et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
MA46471A (fr) Protéines actriib à variant et leurs utilisations
EP3426288A4 (fr) Anticorps anti-pacap et leurs utilisations
EP3454832A4 (fr) Protéines de fusion gdf15 et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
EP3645563A4 (fr) Anticorps anti-fam19a5 et leurs utilisations
MA45233A (fr) Anticorps anti-gitr et leurs utilisations
EP3894548A4 (fr) Polypeptides de cétoréductase modifiés et leurs utilisations
EP3672987A4 (fr) Anticorps anti-apéline et leurs utilisations
MA52235A (fr) Anticorps anti-phf-tau et leurs utilisations